BB102
/ BroadenBio
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
November 21, 2025
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Broadenbio Ltd., Co.
New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor
November 18, 2025
BB102-ST-Ⅰ-02: A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=78 | Recruiting | Sponsor: Broadenbio Ltd., Co. | Trial completion date: Jul 2025 ➔ Dec 2026 | Trial primary completion date: Jan 2025 ➔ Dec 2026
Trial completion date • Trial primary completion date • Solid Tumor
March 06, 2024
BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor effective in multiple xenograft tumor models
(AACR 2024)
- "BB102 is a highly selective and potent reversible-covalent FGFR4 inhibitor with promising efficacy in high expression of both FGF19 and FGFR4, and/or FGFR4 mutated tumor models and good safety in preclinical studies. The phase I study of BB102 is in progress."
Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • FGF19 • FGFR4
February 14, 2024
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=78 | Recruiting | Sponsor: BrodenBio Co., Ltd.
New P1 trial • Oncology • Solid Tumor • FGF19 • FGFR4
1 to 4
Of
4
Go to page
1